Next |
home / stock / xncr / xncr message board
News, Short Squeeze, Breakout and More Instantly...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlig...
2024-04-25 18:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-16 07:00:03 ET Kaveri Pohlman from BTIG issued a price target of $38.00 for XNCR on 2024-04-16 05:16:00. The adjusted price target was set to $38.00. At the time of the announcement, XNCR was trading at $20.11. The overall price target consensus is at $56.00 with...